Literature DB >> 30387188

Increased CDKL3 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma.

Wenguang Ye1, Jian Zhu2,3, Dongjie He4, Dequan Yu4, Haihua Yang2,3, Wei Wang2,3, Mingxin Zhang5, Suna Zhou2,3.   

Abstract

BACKGROUND: Cyclin-dependent kinase-like 3 (CDKL3) is a putative protein serine kinase and plays an important role in the regulation of cell growth and/or differentiation. However, studies on the function of CDKL3 in esophageal squamous cell carcinoma (ESCC) is limited. In our study, we explored the role and prognosis of CDKL3 in ESCC and underlying mechanism.
MATERIALS AND METHODS: The expression of CDKL3 was investigated by quantitative reverse transcription polymerase chain reaction and immunohistochemical staining. CDKL3 expression was downregulated by the RNAi-mediated knockdown. The functions of CDKL3 on cell growth were assessed by Celigo image cytometry, MTT assay, cell-cycle analysis, Annexin V assay, and caspase-3/7 activity analysis. The effect of CDKL3 on cellular invasive was investigated by the Transwell assay. Pathscan Stress Signaling Antibody Array was used to study the underlying mechanism. Additionally, the association between the survival and CDKL3 expression in ESCC were evaluated based on the TCGA data.
RESULTS: CDKL3 was highly expressed in ESCC tissues and cell lines. TE-1 cells transfected with CDKL3-shRNA-lentivirus significantly decreased CDKL3 expression and resulted in inhibiting cell proliferation, inducing the S-phase cell-cycle arrest, attenuating cellular invasive and increasing cell apoptosis. The expression of pERK1/2, p-Akt, p-Smad2, p-p38 mitogen-activated protein kinase, cleaved caspase-7, and phospho-Chk1 were significantly decreased by CDKL3 knockdown. In addition, high expression of CDKL3 was associated with shorter overall survival.
CONCLUSION: Our findings suggest that higher expression of CDKL3 is correlated with poor prognosis in patients with ESCC and play a vital role in the malignant phenotype of ESCC cell lines, which indicating that CDKL3 may be as a new therapeutic target in ESCC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CDKL3; apoptosis; esophageal squamous cell carcinoma (ESCC); prognosis

Year:  2018        PMID: 30387188     DOI: 10.1002/jcb.27991

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

1.  Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration.

Authors:  Xiaohui Duan; Jianhui Yang; Bo Jiang; Wenbin Duan; Rongguang Wei; Hui Zhang; Xianhai Mao
Journal:  Cell Cycle       Date:  2021-03-02       Impact factor: 4.534

2.  CDKL2 Is Associated with HER2 Status and Overall Survival in Gastric Cancer: Comparative Analysis of CDKL2 Protein Expression and Gene Copy Number.

Authors:  Qiong Shao; Fang Wang; Yuxia Xu; Xu Zhang; Wenting Tang; Yanfen Feng; Yue Li
Journal:  Biomed Res Int       Date:  2020-10-31       Impact factor: 3.411

3.  CDKL3 promotes osteosarcoma progression by activating Akt/PKB.

Authors:  Aina He; Lanjing Ma; Yujing Huang; Haijiao Zhang; Wei Duan; Zexu Li; Teng Fei; Junqing Yuan; Hao Wu; Liguo Liu; Yueqing Bai; Wentao Dai; Yonggang Wang; Hongtao Li; Yong Sun; Yaling Wang; Chunyan Wang; Ting Yuan; Qingcheng Yang; Songhai Tian; Min Dong; Ren Sheng; Dongxi Xiang
Journal:  Life Sci Alliance       Date:  2020-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.